Efficacy and safety of ABT-335 (fenofibric acid) in combination with simvastatin in patients with mixed dyslipidemia

A phase 3, randomized, controlled study

Syed M. Mohiuddin, Carl J. Pepine, Maureen T. Kelly, Susan M. Buttler, Carolyn M. Setze, Darryl J. Sleep, James C. Stolzenbach

Research output: Contribution to journalArticle

70 Citations (Scopus)

Abstract

Background: Patients with mixed dyslipidemia often require combination therapy to effectively control lipid abnormalities. This study compared the effects of combination therapy with ABT-335 (a new formulation of fenofibric acid) and simvastatin to ABT-335 and simvastatin monotherapies on lipid and nonlipid parameters in patients with mixed dyslipidemia. Methods: This was a phase 3, multicenter, randomized, double-blind, active-controlled study. A total of 657 patients with mixed dyslipidemia (low-density lipoprotein cholesterol [LDL-C] ≥130 mg/dL, triglycerides [TGs] ≥150 mg/dL, and high-density lipoprotein cholesterol [HDL-C]

Original languageEnglish
Pages (from-to)195-203
Number of pages9
JournalAmerican Heart Journal
Volume157
Issue number1
DOIs
StatePublished - Jan 2009

Fingerprint

Simvastatin
Dyslipidemias
Safety
Lipids
LDL Cholesterol
HDL Cholesterol
Triglycerides
Therapeutics
2-(4-(4-chlorobenzoyl)phenoxy)-2-methylpropanoic acid
fenofibric acid

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine

Cite this

Efficacy and safety of ABT-335 (fenofibric acid) in combination with simvastatin in patients with mixed dyslipidemia : A phase 3, randomized, controlled study. / Mohiuddin, Syed M.; Pepine, Carl J.; Kelly, Maureen T.; Buttler, Susan M.; Setze, Carolyn M.; Sleep, Darryl J.; Stolzenbach, James C.

In: American Heart Journal, Vol. 157, No. 1, 01.2009, p. 195-203.

Research output: Contribution to journalArticle

Mohiuddin, Syed M. ; Pepine, Carl J. ; Kelly, Maureen T. ; Buttler, Susan M. ; Setze, Carolyn M. ; Sleep, Darryl J. ; Stolzenbach, James C. / Efficacy and safety of ABT-335 (fenofibric acid) in combination with simvastatin in patients with mixed dyslipidemia : A phase 3, randomized, controlled study. In: American Heart Journal. 2009 ; Vol. 157, No. 1. pp. 195-203.
@article{75454193e67841fa8ad366c336dd015d,
title = "Efficacy and safety of ABT-335 (fenofibric acid) in combination with simvastatin in patients with mixed dyslipidemia: A phase 3, randomized, controlled study",
abstract = "Background: Patients with mixed dyslipidemia often require combination therapy to effectively control lipid abnormalities. This study compared the effects of combination therapy with ABT-335 (a new formulation of fenofibric acid) and simvastatin to ABT-335 and simvastatin monotherapies on lipid and nonlipid parameters in patients with mixed dyslipidemia. Methods: This was a phase 3, multicenter, randomized, double-blind, active-controlled study. A total of 657 patients with mixed dyslipidemia (low-density lipoprotein cholesterol [LDL-C] ≥130 mg/dL, triglycerides [TGs] ≥150 mg/dL, and high-density lipoprotein cholesterol [HDL-C]",
author = "Mohiuddin, {Syed M.} and Pepine, {Carl J.} and Kelly, {Maureen T.} and Buttler, {Susan M.} and Setze, {Carolyn M.} and Sleep, {Darryl J.} and Stolzenbach, {James C.}",
year = "2009",
month = "1",
doi = "10.1016/j.ahj.2008.08.027",
language = "English",
volume = "157",
pages = "195--203",
journal = "American Heart Journal",
issn = "0002-8703",
publisher = "Mosby Inc.",
number = "1",

}

TY - JOUR

T1 - Efficacy and safety of ABT-335 (fenofibric acid) in combination with simvastatin in patients with mixed dyslipidemia

T2 - A phase 3, randomized, controlled study

AU - Mohiuddin, Syed M.

AU - Pepine, Carl J.

AU - Kelly, Maureen T.

AU - Buttler, Susan M.

AU - Setze, Carolyn M.

AU - Sleep, Darryl J.

AU - Stolzenbach, James C.

PY - 2009/1

Y1 - 2009/1

N2 - Background: Patients with mixed dyslipidemia often require combination therapy to effectively control lipid abnormalities. This study compared the effects of combination therapy with ABT-335 (a new formulation of fenofibric acid) and simvastatin to ABT-335 and simvastatin monotherapies on lipid and nonlipid parameters in patients with mixed dyslipidemia. Methods: This was a phase 3, multicenter, randomized, double-blind, active-controlled study. A total of 657 patients with mixed dyslipidemia (low-density lipoprotein cholesterol [LDL-C] ≥130 mg/dL, triglycerides [TGs] ≥150 mg/dL, and high-density lipoprotein cholesterol [HDL-C]

AB - Background: Patients with mixed dyslipidemia often require combination therapy to effectively control lipid abnormalities. This study compared the effects of combination therapy with ABT-335 (a new formulation of fenofibric acid) and simvastatin to ABT-335 and simvastatin monotherapies on lipid and nonlipid parameters in patients with mixed dyslipidemia. Methods: This was a phase 3, multicenter, randomized, double-blind, active-controlled study. A total of 657 patients with mixed dyslipidemia (low-density lipoprotein cholesterol [LDL-C] ≥130 mg/dL, triglycerides [TGs] ≥150 mg/dL, and high-density lipoprotein cholesterol [HDL-C]

UR - http://www.scopus.com/inward/record.url?scp=57149105884&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=57149105884&partnerID=8YFLogxK

U2 - 10.1016/j.ahj.2008.08.027

DO - 10.1016/j.ahj.2008.08.027

M3 - Article

VL - 157

SP - 195

EP - 203

JO - American Heart Journal

JF - American Heart Journal

SN - 0002-8703

IS - 1

ER -